Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

256
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
256
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

73
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
73
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

127
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
127
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

689
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
689
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

69
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
69
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

62
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
62

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Aberrant Right Subclavian Artery: A Case Report.

Cureus·2026
Same author

Producing concept-motivated signs supports learning of STEM in American Sign Language.

NPJ science of learning·2026
Same author

Enhancing COVID-19 Screening Models With Epidemiological and Mobility Features: Machine-Learning Model Study.

JMIR AI·2026
Same author

Simulation-Based Training in Intraosseous Access: Improving Procedural Skills in Pediatric Residents.

Sage open pediatrics·2025
Same author

IFNγ signaling drives resistance to FLT3 inhibition in acute myeloid leukemia.

iScience·2025
Same author

Infant dietary patterns and early childhood weight outcomes: a secondary analysis from the Starting Early Program Trial.

Research square·2025
Same journal

Vision-language models for human motion understanding: Lessons from stroke rehabilitation.

PLOS digital health·2026
Same journal

A digital marker for stratifying cardiovascular metabolic comorbidities among the middle-aged and elderly adults.

PLOS digital health·2026
Same journal

User engagement in the tuberculosis treatment support tools intervention and its impact on treatment outcomes: A secondary analysis of a pragmatic trial.

PLOS digital health·2026
Same journal

Machine learning for risk stratification of hypertensive disorders of pregnancy: Enhancing clinical efficiency in low-resource antenatal care in Tanzania.

PLOS digital health·2026
Same journal

The trust in AI-generated health advice (TAIGHA) scale and short version (TAIGHA-S): Development and validation study.

PLOS digital health·2026
Same journal

Time-series prediction of adverse birth outcomes in the U.S. using multilayer perceptron neural networks.

PLOS digital health·2026
查看所有相关文章

相关实验视频

Updated: Jul 4, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

通过数据科学优化药物基因组决策.

Amir M Behdani1, Jessica Lai1, Christina Kim1

  • 1Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, Virginia, United States of America.

PLOS digital health
|February 8, 2024
PubMed
概括
此摘要是机器生成的。

患者优化药物基因组学 (POPGx) 简化了基因型导向药物剂量,以改善患者治疗. 该工具通过有效访问药物基因组数据,帮助医疗保健提供者优化药物疗效和安全性.

更多相关视频

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.0K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

相关实验视频

Last Updated: Jul 4, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.0K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.2K

科学领域:

  • 药物基因组学 药物基因组学
  • 在医疗保健中的数据科学.
  • 精准医学是一门精准的医学.

背景情况:

  • 药物的有效性在患者之间有很大差异.
  • 基因型信息可以优化患者的治疗和剂量.
  • 目前的基因剂量信息检索是劳动密集型的.

研究的目的:

  • 描述患者优化药物基因组学 (POPGx) 的发展.
  • 创建一个工具,简化药物遗传学对多种药物治疗方案的剂量建议.
  • 教导患者遗传变异如何影响药物反应.

主要方法:

  • POPGx是使用Konstanz Information Miner (KNIME) 开发的,这是一个没有代码的数据分析环境.
  • 建立了一个KNIME REST API节点,从临床药物遗传学实施联盟 (CPIC) 准则中获取数据.
  • 工作流处理了由CYP450酶代谢的药物,以证明能力.

主要成果:

  • POPGx提供了一种节省时间的方法来检索患者特定的药物和剂量建议.
  • 该程序自动显示当前的CPIC指南建议.
  • 用户输入遗传数据和药物清单,以获得明确的剂量信息.

结论:

  • POPGx简化了医疗保健提供者对药物基因组剂量信息的访问.
  • 该工具增强了临床决策,以提高药物的有效性和安全性.
  • 整合到医疗保健系统可以通过精确的药物基因组学彻底改变患者护理.